NCT04824794: Phase 1/2: GEN3014 Safety Trial in Relapsed or Refractory Hematologic Malignancies
- Recruiting
- Jun 11, 2021
- 1 min read
Updated: May 25, 2022
NCT04824794: Phase 1/2: GEN3014 Safety Trial in Relapsed or Refractory Hematologic Malignancies
GEN3014 Safety Trial in Relapsed or Refractory Hematologic Malignancies
This trial is an open-label, safety trial of GEN3014 (HexaBody®-CD38). The trial consists of two parts: a dose escalation part phase 1, first-in-human (FIH), and an expansion part phase 2a.
Sponsor
Multiple Locations
International Study
ClinicalTrials.gov Identifier: NCT04824794
Official Title: An Open-Label, Multicenter, Phase 1/2 Trial of GEN3014 (HexaBody®-CD38) in Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies
First Posted : April 1, 2021
Click here to see details on ClinicalTrials.gov
Biological: GEN3014 (HexaBody®-CD38)
Anti-CD38 Monoclonal Antibody GEN3014 (Code C179514)
Anti-CD38 Monoclonal Antibody GEN3014
GEN 3014
GEN-3014
GEN3014
HexaBody-CD38
Locations
United States, New Jersey
United States, North Carolina
United States, Wisconsin
Europe
Spain
Denmark
Sweden